Daiichi Sankyo Co Ltd (PK) News - DSKYF

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015...

Venue Change

Tue, Oct 08, 2013 12:00 - Daiichi Sankyo Co., Ltd. (DSKYF: OTC Link) - Venue Change - The symbol, DSKYF, no longer trades on Grey Market. As of...

Glaxo Files for Two Flu Vaccines - Analyst Blog

Recently, GlaxoSmithKline (GSK) announced that it has filed marketing applications for two influenza vaccines. The vaccines, up for approval...

Glaxo and Daiichi to Set Up JV - Analyst Blog

British drugmaker GlaxoSmithKline (GSK) recently announced that it has signed an agreement with Daiichi Sankyo (DSKYF) to form a joint venture...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Daiichi Sankyo Co Ltd (PK) (DSKYF)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DSKYF News

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Venue Change

Glaxo Files for Two Flu Vaccines - Analyst Blog

Glaxo and Daiichi to Set Up JV - Analyst Blog

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

Patients with Hypertension at Risk Due to Physician Inertia

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure

DSKYF Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Daiichi Sankyo Co Ltd (PK) (DSKYF) News

Daiichi Sankyo Co Ltd (PK) (DSKYF)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

DSKYF News

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Venue Change

Glaxo Files for Two Flu Vaccines - Analyst Blog

Glaxo and Daiichi to Set Up JV - Analyst Blog

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

Patients with Hypertension at Risk Due to Physician Inertia

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure

DSKYF Discussion

Your Recent History

Go Ad-Free